W.T. Godbey, Ph.D. 


Intellectual Property

     U.S. Patent No. 7,638,331



Available for

  • Exclusive Licensing
  • Non-exclusive Licensing
  • Scientific Collaboration



Confidential Disclosure Agreement



For more information, please contact:

     Gregory Scott Stein
     Licensing Associate


Novel Apoptosis-Inducing Constructs for Use Against Carcinomas (printable)


Tulane University is actively seeking companies interested in commercializing novel constructs which effectively induce apoptosis in cancer cells. The novel approach employs two caspases to achieve a synergistic effect, resulting in a more substantial level of cell death in the targeted cancer cells.




  • Provides effective initiation of the apoptosis cascade in cancer cells that overexpress cyclooxygenase-2 (Cox-2)
  • Includes use in cancers of the colon, prostate, bladder, stomach, and esophagus



  • Based on proven method of apoptosis to treat cancer
  • Degradation products are packaged and undergo phagocytosis
  • Low toxicity profile

Development Status

This technology has been tested extensively in vitro and in vivo in a mouse model, with results strongly supporting the anti-cancer applications. Human trials are in development. Laboratory work is ongoing to produce more effective species of these constructs.



Related Publications

Tulane Technology Transfer and Intellectual Property Development, New Orleans, LA 70112 504-988-6962